Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Ergomed plc (ERGO) Ordinary 1p

Sell:1,200.00p Buy:1,250.00p 0 Change: 70.00p (5.41%)
FTSE AIM 100:1.28%
Market closed Prices as at close on 4 March 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,200.00p
Buy:1,250.00p
Change: 70.00p (5.41%)
Market closed Prices as at close on 4 March 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1,200.00p
Buy:1,250.00p
Change: 70.00p (5.41%)
Market closed Prices as at close on 4 March 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Ergomed earnings to beat expectations for 2020

    26 January 2021 09:43

    (Sharecast News) - Specialist pharmaceutical service provider Ergomed updated the market on its trading in 2020 on Tuesday, saying it still expected revenue for the year ended 31 December to be in line with...

  • Sunday share tips: Ergomed, Johnson Matthey

    6 December 2020 13:02

    (Sharecast News) - The Mail on Sunday's Midas column recommended readers 'buy' shares of pharmacovigilance specialist Ergomed.

  • Ergomed reports on 'excellent' first half

    21 July 2020 16:26

    (Sharecast News) - Specialised pharmaceutical services company Ergomed said on Tuesday that it had an "excellent" first half, with overall growth in revenue driven by continued demand for its...

  • Ergomed reports decent first quarter

    10 June 2020 07:56

    (Sharecast News) - Specialist pharmaceutical services company Ergomed said on Wednesday that it had a "good" first quarter, with "solid" overall growth in revenue.

  • Ergomed joins Covid-19 therapy programme

    6 April 2020 16:11

    (Sharecast News) - Specialised pharmaceutical services provider Ergomed announced on Monday that it is providing support for a clinical development programme for 'namilumab', a monoclonal antibody...

  • Ergomed to check drug safety for US Covid-19 trial

    30 March 2020 12:19

    (Sharecast News) - Ergomed said it would provide drug safety services for a US trial to assess the benefits of a rheumatoid arthritis treatment for patients suffering from severe coronavirus infections.

  • Ergomed earnings rise as it begins Covid therapy testing

    25 March 2020 15:05

    (Sharecast News) - Pharmaceutical services company Ergomed reported a 26.1% improvement in its revenue to ?68.3m on a comparable basis in its full-year results on Wednesday.

  • Ergomed confirms involvement in Italian Covid-19 study

    18 March 2020 09:20

    (Sharecast News) - Specialist pharmaceutical services company Ergomed announced on Wednesday the start of a study of 'siltuximab', an interleukin-6 targeted monoclonal antibody, for the treatment...

  • Ergomed sees FY earnings beating expectations

    29 January 2020 11:04

    (Sharecast News) - Pharmaceutical industry services provider Ergomed said on Wednesday that it had continued to deliver strong year-on-year top-line growth and now expects full-year underlying earnings to...

  • Ergomed acquires Ashfield Pharmacovigilance from UDG

    13 January 2020 10:39

    (Sharecast News) - Pharmaceutical services provider Ergomed announced the acquisition of Ashfield Pharmacovigilance, a specialist pharmacovigilance services provider based in Cary in the 'Research...

  • Ergomed names Lewis Cameron as next COO

    2 December 2019 08:05

    (Sharecast News) - Pharmaceutical industry services provider Ergomed named Lewis Cameron as its next chief operating officer on Monday.

  • Director dealings: Ergomed founder ups stake

    25 June 2019 15:51

    (Sharecast News) - Ergomed revealed on Tuesday that executive chairman Dr Miroslav Reljanovic had acquired a total of 200,000 ordinary shares in the AIM-listed biotechnology firm.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2021. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.